Market Place
Sourcing Support
NGM Bio Doses 1st Patient In Ph 2 Study For Hyperemesis Gravidarum
24 Feb 2025 //
GLOBENEWSWIRE
NGM Bio Announces Appointment of Wendy as Chief Medical Officer
04 Feb 2025 //
GLOBENEWSWIRE
VC firm pens $608M deal to direct NGM MASH drug to rare disease
20 Dec 2024 //
FIERCE BIOTECH
NGM Bio & KdT Ventures Enter Agreement for NGM313 Agonist Drug
19 Dec 2024 //
GLOBENEWSWIRE
NGM Bio Raises $122M For PSC And Hyperemesis Gravidarum Trials
17 Jul 2024 //
GLOBENEWSWIRE
3 months after taking NGM Bio private, VC firm oversees biotech’s $122M series A
17 Jul 2024 //
FIERCE BIOTECH
NGM Bio Announces Closing of Tender Offer
05 Apr 2024 //
GLOBENEWSWIRE
NGM Bio to Present Two Posters Highlighting of Ongoing Ph 1/2 Trial of NGM707
19 Mar 2024 //
GLOBENEWSWIRE
NGM BIO INVESTOR ALERT by the Former Attorney General of Louisiana
13 Mar 2024 //
BUSINESSWIRE
NGM Bio Reports Fourth Quarter and Full Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
NGM Biopharma Investor Alert By The Former Attorney General Of Louisiana
27 Feb 2024 //
BUSINESSWIRE
NGM Bio Has Entered into a Agreement and Plan of Merger with Certain Affiliates
26 Feb 2024 //
GLOBENEWSWIRE
NGM to go private as part of $135M buyout by VC firm Column
26 Feb 2024 //
FIERCE BIOTECH
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
20 Feb 2024 //
GLOBENEWSWIRE
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
17 Jan 2024 //
GLOBENEWSWIRE
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707
09 Jan 2024 //
GLOBENEWSWIRE
NGM Bio subject of take-private bid by institutional investor The Column Group
03 Jan 2024 //
ENDPTS
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin
13 Nov 2023 //
GLOBENEWSWIRE
NGM Bio to Participate in Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
NGM Bio Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
NGM Bio Announces Plenary Presentation of Data from Phase 2b Trial of Aldafermin
11 Oct 2023 //
GLOBENEWSWIRE
NGM Bio Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
NGM Bio to Participate in Upcoming Investor Conferences
25 May 2023 //
GLOBENEWSWIRE
NGM Bio Announces Presentation of Data from Ph2 Investigator Trial of Aldafermin
08 May 2023 //
GLOBENEWSWIRE
NGM Bio Reports 1Q 2023 FYR & &s Business Highlights, Topline ALPINE 4 Data
04 May 2023 //
GLOBENEWSWIRE
Following clinical setbacks, NGM Bio lays off 33% of staffers as founder departs
06 Apr 2023 //
ENDPTS
NGM Bio CEO reveals what led to 33% head count reduction
05 Apr 2023 //
FIERCE BIOTECH
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
NGM Bio Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
12 Jan 2023 //
GLOBENEWSWIRE
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
09 Jan 2023 //
GLOBENEWSWIRE
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
22 Dec 2022 //
FIERCEBIOTECH
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936
12 Dec 2022 //
GLOBENEWSWIRE
NGM Bio Presents Preliminary Data from Ph1 Monotherapy Dose Trial of NGM707
07 Dec 2022 //
GLOBENEWSWIRE
NGM Bio Announces Poster Presentation Initial Findings from Ph1a Trial of NGM707
07 Nov 2022 //
GLOBENEWSWIRE
NGM Bio Announces Poster Presentation Featuring Preclinical of NGM936
04 Nov 2022 //
GLOBENEWSWIRE
NGM Bio Announces Presentation of Post-Hoc from CATALINA Phase 2 Trial of NGM621
03 Nov 2022 //
GLOBENEWSWIRE
NGM Bio Provides Business Highlights and Reports 3Q FYR
03 Nov 2022 //
GLOBENEWSWIRE
Merck partner NGM takes stock beating after PhII failure in eye disease
18 Oct 2022 //
ENDPTS
NGM Bio to Host Conference Call to Discuss Topline Results from Ph2 of NGM621
17 Oct 2022 //
GLOBENEWSWIRE
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621
17 Oct 2022 //
GLOBENEWSWIRE
NGM Bio Presents Updated Preliminary Findings from Ongoing P1b Trial of NGM120
13 Sep 2022 //
GLOBENEWSWIRE
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Trial of NGM120
06 Sep 2022 //
GLOBENEWSWIRE
NGM Bio Announces Presentations from the Ongoing P1a Dose Trial of NGM120
15 Aug 2022 //
GLOBENEWSWIRE
NGM Bio Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
30 Jun 2022 //
GLOBENEWSWIRE
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
23 Jun 2022 //
GLOBENEWSWIRE
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
24 May 2022 //
GLOBENEWSWIRE
NGM Bio Initiates PI/Ib Clinical Study of NGM438 for Advanced Solid Tumors
12 May 2022 //
GLOBENEWSWIRE
NGM Bio Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
20 Apr 2022 //
GLOBENEWSWIRE
NGM Bio to Participate in Upcoming Investor Conferences
20 Apr 2022 //
GLOBENEWSWIRE
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR
08 Apr 2022 //
GLOBENEWSWIRE
NGM Bio Initiates Phase 1/1b Trial of NGM831 for Advanced Solid Tumors
31 Mar 2022 //
GLOBENEWSWIRE
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
21 Mar 2022 //
GLOBENEWSWIRE
NGM Bio says Oral and Late-Breaking Poster Presentations at AACR
08 Mar 2022 //
GLOBENEWSWIRE
NGM Bio Provides Business Highlights and Reports Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
GLOBENEWSWIRE
NGM Bio’s NGM621 Receives FTD from FDA for Geographic Atrophy Secondary to ARMD
07 Feb 2022 //
GLOBENEWSWIRE
NGM Bio Outlines 2022 Strategic Priorities Across Its Clinical-Stage Programs
10 Jan 2022 //
GLOBENEWSWIRE
